Researchers
Adriana Montano
Summary
This invention relates to methods of treating patients with osteopenia, osteoporosis, osteomalacia. osteoanhritis, and hypophosphatasia using miglustat. It also relates to methods for improving bone mineral density. Miglustat ((2R,3R,4R,5S)- 1 -butyl-2-(hydroxymethyl)piperidine- 3,4,5-triol) is an iminosugar (N-butyldeoxynojirimyein) known for inhibiting glucosylceramide synthase biosynthesis and used for treating the lysosomal storage disorder Gaucher’s disease (GD). A study on patients with Type L GD found that Miglustat treatment increased BMD and alleviated bone pain.
Intellectual Property Status
- U.S. patent pending